How much profit has Sanofi made this year?
Sanofi has made 9.67 B EUR this year.
Sanofi Net Income 2024
Sanofi Net Income
9.67 B EUR
Ticker
SAN.PA
ISIN
FR0000120578
WKN
920657
In 2024, Sanofi's profit amounted to 9.67 B EUR, a 79.07% increase from the 5.4 B EUR profit recorded in the previous year.
The Sanofi Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2029e | 15.41 |
| 2028e | 14.25 |
| 2027e | 12.93 |
| 2026e | 11.96 |
| 2025e | 10.92 |
| 2024e | 9.67 |
| 2023 | 5.4 |
| 2022 | 8.37 |
| 2021 | 6.22 |
| 2020 | 12.29 |
| 2019 | 2.75 |
| 2018 | 4.31 |
| 2017 | 8.42 |
| 2016 | 4.71 |
| 2015 | 4.29 |
| 2014 | 4.39 |
| 2013 | 3.72 |
| 2012 | 4.89 |
| 2011 | 5.69 |
| 2010 | 5.47 |
| 2009 | 5.27 |
| 2008 | 3.85 |
| 2007 | 5.26 |
| 2006 | 4.01 |
| 2005 | 2.26 |
| 2004 | 1.99 |
Sanofi Revenue, EBIT, Net Income FR0000120578 · 920657
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Sanofi, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sanofi from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sanofi’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Sanofi. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Sanofi’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Sanofi’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sanofi’s growth potential.
Sanofi Revenue, EBIT and net profit per share
| Date | Sanofi Revenue | Sanofi EBIT | Sanofi Net Income |
|---|---|---|---|
| 2029e | 62.11 B undefined | 18.8 B undefined | 15.41 B undefined |
| 2028e | 59.23 B undefined | 18.15 B undefined | 14.25 B undefined |
| 2027e | 56.36 B undefined | 16.7 B undefined | 12.93 B undefined |
| 2026e | 53.71 B undefined | 14.55 B undefined | 11.96 B undefined |
| 2025e | 50.66 B undefined | 13.18 B undefined | 10.92 B undefined |
| 2024e | 47.5 B undefined | 11.51 B undefined | 9.67 B undefined |
| 2023 | 46.44 B undefined | 9.41 B undefined | 5.4 B undefined |
| 2022 | 45.39 B undefined | 10.05 B undefined | 8.37 B undefined |
| 2021 | 39.18 B undefined | 8.37 B undefined | 6.22 B undefined |
| 2020 | 37.37 B undefined | 7.38 B undefined | 12.29 B undefined |
| 2019 | 37.63 B undefined | 6.78 B undefined | 2.75 B undefined |
| 2018 | 35.68 B undefined | 6.26 B undefined | 4.31 B undefined |
| 2017 | 36.22 B undefined | 7.2 B undefined | 8.42 B undefined |
| 2016 | 34.7 B undefined | 7.53 B undefined | 4.71 B undefined |
| 2015 | 34.86 B undefined | 7.13 B undefined | 4.29 B undefined |
| 2014 | 32 B undefined | 6.74 B undefined | 4.39 B undefined |
| 2013 | 31.29 B undefined | 6.36 B undefined | 3.72 B undefined |
| 2012 | 35.96 B undefined | 7.88 B undefined | 4.89 B undefined |
| 2011 | 35.06 B undefined | 7.5 B undefined | 5.69 B undefined |
| 2010 | 34.04 B undefined | 8.49 B undefined | 5.47 B undefined |
| 2009 | 31.23 B undefined | 7.89 B undefined | 5.27 B undefined |
| 2008 | 28.82 B undefined | 6.46 B undefined | 3.85 B undefined |
| 2007 | 29.21 B undefined | 6.11 B undefined | 5.26 B undefined |
| 2006 | 29.49 B undefined | 5.73 B undefined | 4.01 B undefined |
| 2005 | 28.51 B undefined | 4.83 B undefined | 2.26 B undefined |
| 2004 | 15.73 B undefined | 3.11 B undefined | 1.99 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 15.73 B EUR | 3.11 B EUR | 1.99 B EUR |
| 2005 | 28.51 B EUR | 4.83 B EUR | 2.26 B EUR |
| 2006 | 29.49 B EUR | 5.73 B EUR | 4.01 B EUR |
| 2007 | 29.21 B EUR | 6.11 B EUR | 5.26 B EUR |
| 2008 | 28.82 B EUR | 6.46 B EUR | 3.85 B EUR |
| 2009 | 31.23 B EUR | 7.89 B EUR | 5.27 B EUR |
| 2010 | 34.04 B EUR | 8.49 B EUR | 5.47 B EUR |
| 2011 | 35.06 B EUR | 7.5 B EUR | 5.69 B EUR |
| 2012 | 35.96 B EUR | 7.88 B EUR | 4.89 B EUR |
| 2013 | 31.29 B EUR | 6.36 B EUR | 3.72 B EUR |
| 2014 | 32 B EUR | 6.74 B EUR | 4.39 B EUR |
| 2015 | 34.86 B EUR | 7.13 B EUR | 4.29 B EUR |
| 2016 | 34.7 B EUR | 7.53 B EUR | 4.71 B EUR |
| 2017 | 36.22 B EUR | 7.2 B EUR | 8.42 B EUR |
| 2018 | 35.68 B EUR | 6.26 B EUR | 4.31 B EUR |
| 2019 | 37.63 B EUR | 6.78 B EUR | 2.75 B EUR |
| 2020 | 37.37 B EUR | 7.38 B EUR | 12.29 B EUR |
| 2021 | 39.18 B EUR | 8.37 B EUR | 6.22 B EUR |
| 2022 | 45.39 B EUR | 10.05 B EUR | 8.37 B EUR |
| 2023 | 46.44 B EUR | 9.41 B EUR | 5.4 B EUR |
| 2024e | 47.5 B EUR | 11.51 B EUR | 9.67 B EUR |
| 2025e | 50.66 B EUR | 13.18 B EUR | 10.92 B EUR |
| 2026e | 53.71 B EUR | 14.55 B EUR | 11.96 B EUR |
| 2027e | 56.36 B EUR | 16.7 B EUR | 12.93 B EUR |
| 2028e | 59.23 B EUR | 18.15 B EUR | 14.25 B EUR |
| 2029e | 62.11 B EUR | 18.8 B EUR | 15.41 B EUR |
Sanofi stock margins FR0000120578 · 920657
The Sanofi margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sanofi. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sanofi.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Sanofi's sales revenue. A higher gross margin percentage indicates that the Sanofi retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Sanofi's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Sanofi's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sanofi's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sanofi. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sanofi's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Sanofi Margin History
| Sanofi Gross margin | Sanofi Profit margin | Sanofi EBIT margin | Sanofi Profit margin |
|---|---|---|---|
| 2029e | 69.35 % | 30.27 % | 24.81 % |
| 2028e | 69.35 % | 30.65 % | 24.05 % |
| 2027e | 69.35 % | 29.63 % | 22.94 % |
| 2026e | 69.35 % | 27.09 % | 22.26 % |
| 2025e | 69.35 % | 26.01 % | 21.56 % |
| 2024e | 69.35 % | 24.23 % | 20.36 % |
| 2023 | 69.35 % | 20.27 % | 11.63 % |
| 2022 | 69.83 % | 22.14 % | 18.44 % |
| 2021 | 68.72 % | 21.35 % | 15.89 % |
| 2020 | 67.46 % | 19.76 % | 32.9 % |
| 2019 | 68.17 % | 18.01 % | 7.32 % |
| 2018 | 67.95 % | 17.53 % | 12.07 % |
| 2017 | 67.94 % | 19.88 % | 23.24 % |
| 2016 | 69.16 % | 21.69 % | 13.57 % |
| 2015 | 68.68 % | 20.46 % | 12.3 % |
| 2014 | 68.03 % | 21.06 % | 13.72 % |
| 2013 | 67.08 % | 20.32 % | 11.88 % |
| 2012 | 69.14 % | 21.92 % | 13.6 % |
| 2011 | 68.9 % | 21.39 % | 16.24 % |
| 2010 | 72.39 % | 24.94 % | 16.06 % |
| 2009 | 74.04 % | 25.25 % | 16.86 % |
| 2008 | 74.54 % | 22.41 % | 13.36 % |
| 2007 | 74.08 % | 20.91 % | 18.02 % |
| 2006 | 74.27 % | 19.43 % | 13.58 % |
| 2005 | 73.46 % | 16.95 % | 7.92 % |
| 2004 | 71.79 % | 19.74 % | 12.62 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 71.79 % | 19.74 % | 12.62 % |
| 2005 | 73.46 % | 16.95 % | 7.92 % |
| 2006 | 74.27 % | 19.43 % | 13.58 % |
| 2007 | 74.08 % | 20.91 % | 18.02 % |
| 2008 | 74.54 % | 22.41 % | 13.36 % |
| 2009 | 74.04 % | 25.25 % | 16.86 % |
| 2010 | 72.39 % | 24.94 % | 16.06 % |
| 2011 | 68.9 % | 21.39 % | 16.24 % |
| 2012 | 69.14 % | 21.92 % | 13.6 % |
| 2013 | 67.08 % | 20.32 % | 11.88 % |
| 2014 | 68.03 % | 21.06 % | 13.72 % |
| 2015 | 68.68 % | 20.46 % | 12.3 % |
| 2016 | 69.16 % | 21.69 % | 13.57 % |
| 2017 | 67.94 % | 19.88 % | 23.24 % |
| 2018 | 67.95 % | 17.53 % | 12.07 % |
| 2019 | 68.17 % | 18.01 % | 7.32 % |
| 2020 | 67.46 % | 19.76 % | 32.9 % |
| 2021 | 68.72 % | 21.35 % | 15.89 % |
| 2022 | 69.83 % | 22.14 % | 18.44 % |
| 2023 | 69.35 % | 20.27 % | 11.63 % |
| 2024e | 69.35 % | 24.23 % | 20.36 % |
| 2025e | 69.35 % | 26.01 % | 21.56 % |
| 2026e | 69.35 % | 27.09 % | 22.26 % |
| 2027e | 69.35 % | 29.63 % | 22.94 % |
| 2028e | 69.35 % | 30.65 % | 24.05 % |
| 2029e | 69.35 % | 30.27 % | 24.81 % |
Sanofi Aktienanalyse
What does Sanofi do?
Sanofi SA is a French company that was formed in 1973 from a merger of two French pharmaceutical and biotechnology companies. It is one of the largest players in the healthcare industry worldwide and employs over 100,000 employees. The objective of Sanofi is to improve people's lives through innovative medicines and therapies. In this regard, the company pursues a comprehensive business model that focuses on both research and development, as well as the production and distribution of medications and vaccines. The company has different divisions and product lines, which are divided into three business areas: Innovative Medicine, Consumer Healthcare, and Generic Pharmaceuticals. Innovative Medicine utilizes state-of-the-art technologies and scientific knowledge to treat the most challenging diseases. In the area of Consumer Healthcare, the company offers a wide range of over-the-counter products such as vitamins, dietary supplements, cough and cold remedies, as well as oral and dental health products. In the Generic Pharmaceuticals field, the company produces more cost-effective alternatives to expensive brand-name products, providing a variety of generic medications. Sanofi is a leading manufacturer of medications that are of great significance in various areas such as diabetes, oncology, cardiovascular diseases, and neurology. In recent years, the company has also established a strong presence in the field of vaccines. Here, Sanofi develops and produces innovative vaccines against COVID-19, influenza, and other infectious diseases. Sanofi is present in more than 170 countries and collaborates closely with physicians, research institutions, and health authorities to improve healthcare worldwide. The company conducts research and development in various disciplines and invests a significant amount each year in the development of innovative medicines and therapies. Overall, Sanofi SA is an emerging company in the pharmaceutical and healthcare sector. The portfolio of products and therapies offered by Sanofi is extensive and covers many areas of healthcare. Sanofi relies on continuous innovation and continuously works to improve healthcare and enhance the lives of people worldwide. Sanofi ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Sanofi's Profit Margins
The profit margins of Sanofi represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Sanofi's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Sanofi's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Sanofi's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Sanofi’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Sanofi stock
How has the profit developed compared to last year?
The profit has increased by 79.07% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Sanofi publish its earnings?
Sanofi publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Sanofi?
The profits of Sanofi are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Sanofi?
You can learn more about the earnings of Sanofi by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Sanofi pay?
Over the past 12 months, Sanofi paid a dividend of 3.56 EUR . This corresponds to a dividend yield of about 3.88 %. For the coming 12 months, Sanofi is expected to pay a dividend of 3.76 EUR.
What is the dividend yield of Sanofi?
The current dividend yield of Sanofi is 3.88 %.
When does Sanofi pay dividends?
Sanofi pays a quarterly dividend. This is distributed in the months of June, June, June, June.
How secure is the dividend of Sanofi?
Sanofi paid dividends every year for the past 26 years.
What is the dividend of Sanofi?
For the upcoming 12 months, dividends amounting to 3.76 EUR are expected. This corresponds to a dividend yield of 4.09 %.
In which sector is Sanofi located?
Sanofi is assigned to the 'Health' sector.
Wann musste ich die Aktien von Sanofi kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Sanofi from 5/15/2024 amounting to 3.76 EUR, you needed to have the stock in your portfolio before the ex-date on 5/13/2024.
When did Sanofi pay the last dividend?
The last dividend was paid out on 5/15/2024.
What was the dividend of Sanofi in the year 2023?
In the year 2023, Sanofi distributed 3.313 EUR as dividends.
In which currency does Sanofi pay out the dividend?
The dividends of Sanofi are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Sanofi stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Andere Kennzahlen von Sanofi
Our stock analysis for Sanofi Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sanofi Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
